Investment
Features
FeesSafety
Academy
More
Pluang+

Zhibao Labuan Re expands reinsurance operations into Hong Kong and Southeast Asia with key partnerships.

Market News
18 Sep 2026
Newsfile Corp
View Source
Bullish
Zhibao Labuan Re expands reinsurance operations into Hong Kong and Southeast Asia with key partnerships.

Zhibao Technology's subsidiary, Zhibao Labuan Reinsurance, is expanding its reinsurance business into Hong Kong and Southeast Asia, collaborating with top reinsurers in Singapore and Hong Kong. This expansion targets medical, accident, property, and liability insurance lines and leverages Zhibao Technology's strengthened balance sheet to boost underwriting capacity. The move aims to capture high-value reinsurance opportunities outside mainland China and deepen regional risk-transfer capabilities, supporting the company's broader overseas growth strategy.

Zhibao Technology's subsidiary Zhibao Labuan Re is expanding its reinsurance business in Hong Kong and Southeast Asia. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 18, 2026 19:02 WIB: Of 81 priced Financials-sector US stocks tradable on Pluang, 27 rose and 48 fell today. BTBT was priced at USD 1.57 with a 1-day change of +2.61%, SAN at USD 14.44 with -2.56%, and KB at USD 126.60 with -2.48%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
46 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App